Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 12, 2020
Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers Etienne Jornod to step down as Executive Chairman. Jacques...
-
Mar 3, 2020
St Gallen, 3 March 2020 - Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This...
-
Feb 20, 2020
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China Gives Vifor Pharma access to largest iron...
-
Feb 17, 2020
St Gallen, 17 February 2020 – Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to...
-
Feb 13, 2020Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative 13 Feb 2020 PHILADELPHIA – February 13, 2020 – Researchers at the...
-
Feb 12, 2020
CSL Limited's statement on Coronavirus Coronavirus is quite different to influenza virus so it is not a core area of focus for CSL or Seqirus. However, we have investigated possible adjacencies in...
-
Feb 11, 2020CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
KING OF PRUSSIA, Pa.– February 11, 2020 – Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...
-
Jan 22, 2020
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than...
-
Jan 21, 2020This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries
KING OF PRUSSIA, Pa., 21 January 2020 – Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different...
-
Jan 10, 2020
Melbourne, Australia 10 Jan 2020 Melbourne researchers have determined the molecular basis for how an important component of the immune system, called gamma-delta T cells, detects infections and...
-
Jan 9, 2020Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa. 09 Jan 2020 Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th...
-
Dec 14, 2019
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...
-
Dec 11, 2019
Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...
-
Dec 9, 2019First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...
-
Dec 9, 2019
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...
-
Dec 4, 2019Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing
Sydney, Australia 04 Dec 2019 CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product...
-
Nov 26, 2019
For a fifth consecutive year, Iron Deficiency Day aims to inform about the impact and symptoms of iron deficiency Iron Deficiency Day 2019 encourages people to ‘take iron seriously’ Supported...
-
Nov 26, 2019
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity...
-
Nov 18, 2019
St Gallen, 18 November 2019 – Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020. Lee Heeson...
-
Oct 23, 2019Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
KING OF PRUSSIA, Pa. – 23 October 2019 – Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for...
-
Oct 18, 2019
CSL statement in response to media reports on case against Joseph Chiao The Sydney Morning Herald on 18 October 2019 reported that former CSL employee Dr Joseph Chiao ‘stole patient data’. CSL...
-
Oct 14, 2019
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...
-
Oct 10, 2019
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...
-
Sep 27, 2019• Focuses on Patients Through Disease Awareness Support Activities
MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the
-
Sep 26, 2019
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...